NeuroSense Therapeutics Ltd (NASDAQ: NRSN): To Buy Or Not To Buy, That Is The Question

After grabbing 11702.0 shares, the institutional investor is now in possession of 11702.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.09% having worth around $5395.0. Moreover, UBS Securities LLC increased its share by 9665.0 to have a control over 9665.0 shares. NeuroSense Therapeutics Ltd (NRSN) concluded trading […]

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.